Table 4.
Adverse events by treatment group
| Study Group, No. (%) |
||||||
|---|---|---|---|---|---|---|
| Adverse event | Natamycin only (N = 26) | Natamycin + CXL (N = 27) | Amphotericin only (N = 30) | Amphotericin + CXL (N = 28) | Total | P-value a |
| Endophthalmitis | -- | -- | 1 (3) | -- | 1 | |
| Glaucoma | -- | -- | -- | -- | -- | |
| Median tarsorrhaphy | -- | -- | -- | 1 (4) | 1 | |
| Medication reaction | -- | -- | -- | -- | -- | |
| Perforation | 2 (8) | 1 (4) | 4 (13) | 3 (11) | 10 | |
| Therapeutic penetrating keratoplasty | 5 (19) | 5 (19) | 5 (17) | 3 (1) | 18 | |
| Total | 7 | 6 | 11 | 7 | 31 | 0.99 |
a
Fisher’s exact comparing number of people with any adverse event in each arm
Abbreviations: No. = number